PsiOxus Therapeutics expands clinical studies for immuno-oncolytic treatment following positive response to intravenous delivery
Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications
OXFORD – 16 April 2015
PsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UK based biotechnology company developing innovative oncolytic immuno-oncology treatments for cancer, has expanded two of its on-going phase I studies using its anti-cancer treatment candidate, enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus. The expanded studies, introduce a number of additional cancer types into the programme, as a result of phase I data demonstrating the successful tumour delivery of EnAd through intravenous administration. The treatment was generally well tolerated with repeated dosing. PsiOxus has already enrolled its first patients in each indication of the expanded studies.
MoA study to target non-small cell lung, bladder and kidney cancer
The initial study, a phase I mechanism of action (MoA) study of intra-tumoural and intravenous administration of EnAd in colon cancer patients, has been expanded to include intravenous delivery to three additional tumour types, non-small cell lung, urothelial bladder and renal cell cancer. Initial results of the MoA study in colon cancer found that intravenous delivery was as effective as intra-tumoural delivery. Additionally, virus replication was reported in the tumour tissue but not the surrounding normal cells, while CD8+ T-cells were shown to have successfully infiltrated the tumour, which is not normally seen in most colon cancers.
EVOLVE study moves to include repeat intravenous dosing
The EVOLVE (EValuating OncoLytic Vaccine Efficacy) trial has expanded to include repeat intravenous dosing of EnAd in metastatic urothelial bladder cancer. EVOLVE is a first in human phase I/II study to determine the dose, safety, tolerability and potential efficacy of EnAd when delivered intravenously to patients with epithelial cancers. It is the first clinical study to report that live replicating oncolytic virus has been recovered directly from the blood stream of cancer patients.
Results of this dose escalation study identified a phase II dose for single and repeat dosing of EnAd via intravenous administration. This feature of EnAd distinguishes it from most other oncolytic viruses, where effective delivery to tumours via intravenous administration is not seen.
Dr Christine Wilkinson-Blanc, CMO of PsiOxus, commented: “To date, convincing clinical success with oncolytic viruses has been associated largely with intratumoural delivery, and little evidence existed to prove that the systemic delivery of viruses to tumour cells by intravenous administration could be successful. The initial results of our clinical programme suggest that EnAd can target tumour cells following intravenous administration and then replicate. This marks a significant breakthrough in the development and utility of oncolytic viruses in cancer.”
Progress of the EnAd program is also being driven by the company’s next generation “Armed EnAd” anti-cancer therapeutic platform, which makes it possible to further enhance EnAd with genetic instructions for specific anti-cancer molecules such as therapeutic antibodies, which are then produced “in situ” in the tumours. Full details can be found on the PsiOxus website.